Efficacy and price comparison of Indian generic drugs of Obeticholic acid

Obeticholic acid Acid) is a targeted drug used to treat chronic hepatobiliary diseases such as primary biliary cholangitis (PBC). It regulates bile acid metabolism by activating the farnesolX receptor (FXR), thereby reducing liver inflammation and fibrosis. In many European and American countries, obeticholic acid has been approved as a second-line treatment for patients with insufficient response to ursodeoxycholic acid, and its efficacy is widely recognized. However, the drug has not yet been officially approved for marketing in mainland China. If domestic patients want to use it, they must obtain it through overseas channels.

Currently, there are both original version of obeticholic acid and generic versions from India and other countries on the market. Original drugs are usually produced by Intercept Pharmaceuticals and are relatively expensive. The generic version produced by the Indian pharmaceutical company Mylan not only has the same active ingredients, but also basically meets international standards in terms of quality control and clinical effects. According to patient feedback, Indian generic drugs have little difference in efficacy from the original drugs, and have good effects on controlling PBC symptoms and improving liver enzyme levels.

In terms of price, the original drug of obeticholic acid often sells for thousands or even tens of thousands of yuan per box, which poses a considerable burden to patients undergoing long-term treatment. The price of the Indian generic version is significantly more affordable. Currently, the price of 50 tablets of generic drugs on the market is less than 1,000 yuan, making it the first choice for many patients to purchase drugs overseas. Although generic drugs do not have the patent protection of original drugs, on the basis of meeting national drug standards, their efficacy and safety have been recognized by more and more patients in practical applications.

Overall, the Indian version of obeticholic acid generics provides a viable alternative for patients who cannot afford the high cost of original drugs. Although it still needs to be purchased through overseas channels, with its lower price and similar efficacy, it has become the treatment dependence of many PBC patients. In the future, if the drug can be officially launched in China and included in medical insurance, it is expected to further alleviate the financial pressure on patients.

Reference materials:https://www.drugs.com/